* AAs were the first symptom of IAS in 52% of patients, and nearly a quarter had multiple AAs documented.
* The study found a moderate incidence of severe outcomes, including a yearly primary endpoint rate of 1.4%, with younger patients experiencing higher risks and other complications affecting some patients as well.
Genetic testing is crucial for diagnosing short QT syndrome, a rare inherited condition that leads to dangerous heart rhythms and is marked by short QT intervals on an ECG.
Researchers reviewed and updated knowledge about 34 rare genetic variants linked to short QT syndrome, identifying only nine that definitively cause the condition.
The variants were found in four main genes (KCNQ1, KCNH2, KCNJ2, SLC4A3), highlighting the importance of reanalyzing genetic data to improve patient care and early identification of at-risk individuals.
Risk stratification for patients with drug-induced type-1 Brugada syndrome is difficult, and the usefulness of electrophysiological studies (EPS) is unclear.
A systematic literature search categorized patients into three groups based on EPS results: positive, negative, and no EPS conducted.
The study found no significant differences in the rates of arrhythmia events among these groups over an average follow-up of 5.1 years, suggesting EPS may not enhance long-term prognosis in these patients.